Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2009-03-31 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Announces Milestone in Phase III Trial for CF 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release from Pharmaxis announcing a milestone in a Phase III clinical trial for a pharmaceutical product (Bronchitol) targeting cystic fibrosis. It discusses trial completion, regulatory designations, and future expectations but does not contain financial data, earnings, or detailed financial reports. It is a public announcement related to clinical trial progress and regulatory status rather than a financial report or regulatory filing. The document is not an earnings release, annual report, or any other financial filing type. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other specific categories.
2009-03-31 English
Change in substantial holding 2 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001 Section 671B, titled 'Notice of Change of Interests of Substantial Holder.' It details changes in voting power and relevant interests of a substantial shareholder in a company, including dates, number of shares, and nature of changes. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2009-03-26 English
Pharmaxis Appoints French Distributor for Aridol 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing the appointment of a French distributor for a pharmaceutical product (Aridol) by Pharmaxis. It contains no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no earnings data, and no legal or merger information. It is a corporate announcement about a commercial partnership and market development. The document is short (about 5000 characters) and reads like a press release rather than a formal financial or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2009-03-10 English
Aridol New Drug Application Submitted to FDA 2 pages ?Kb
Capital/Financing Update Classification · 90% confidence The document is a media release announcing the submission of a New Drug Application (NDA) to the U.S. FDA for a pharmaceutical product called Aridol. It is a corporate announcement about a regulatory milestone related to drug approval, not a financial report, earnings release, or management discussion. The content focuses on the drug development and regulatory submission, which is typical of a Capital/Financing Update or Regulatory Filing. However, since it is a media release about a regulatory submission and not a financial or capital structure update, the best fitting category is Capital/Financing Update (CAP), as it relates to a significant corporate development impacting the company's product pipeline and potential future revenue streams. The document is not a report itself but an announcement of a significant corporate event related to financing and product development.
2009-03-01 English
Pharmaxis Builds Senior Management Team 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is a media release announcing the appointment of a new senior management team member, specifically the Chief Medical Officer. It focuses on management changes and does not contain financial data, regulatory filings, or report publications. The content aligns with announcements about changes in the company's board or senior management. The document length is 3661 characters, which is relatively short and consistent with a management announcement rather than a full report or detailed filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2009-02-16 English
Change in substantial holding 6 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of Change of Interests of Substantial Holder filed under section 671B of the Corporations Act 2001. It details changes in voting power and shareholdings of a substantial shareholder (Fortis Investment Management Australia Limited) in Pharmaxis Limited. The document includes specifics about share purchases and sales, voting power percentages, and relevant interests. This type of filing corresponds to notifications of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it is not a general regulatory filing or other report type. Therefore, the correct classification is MRQ with high confidence.
2009-02-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.